Teva Reports Q4 and Full Year 2021 Business Results

"In 2021 Teva delivered solid results, generating strong cash flow and improving our profitability. While COVID-19 continued to impact patient behavior and global prescribing patterns, we continued to optimize our supply chain and manufacturing capabilities to provide essential medicines to the millions of patients who rely on us throughout the world. We improved our gross and operating margin and reduced our net debt, keeping us on our path to achieve our 2023 long-term goals.

Looking forward to 2022, we expect to see continued growth of our key products AUSTEDO® and AJOVY®, as well as to continue to advance our core business through the launch of high quality generic medicines around the world. We are also excited about the expected FDA approval and launch of Risperidone LAI, an important treatment for patients suffering from schizophrenia.

I'm very pleased with the agreement we reached with the state of Texas, the second most populous state in the U.S. Not only does it mark a further step in resolving our legacy opioids litigation more broadly, but importantly also makes critical medicines part of the solution when addressing the opioids epidemic. While the agreement includes no admission of wrongdoing, it remains in our best interest to put these cases behind us and continue to focus on the patients we serve every day."

Kåre Schultz
President & Chief Executive Officer

2021 Financial Results

	Revenue	EPS*	Free Cash Flow
Q4 results	$4.1 billion	$0.77	$716 million
2021 full year results	$15.9 billion	$2.58	$2.2 billion
2021 revised guidance	$16.0- $16.4 billion	$2.50 - $2.70 *Non-GAAP EPS	$2.0 - $2.3 billion

Revenues

EPS*



Free Cash Flow

Key Products - Leveraging our growth engines in 2021:

AJOVY
Continued growth in the U.S.; launched in most European countries, in Japan and in certain other countries in our International Markets; auto-injector launched in Canada

AUSTEDO
Launched in China for the treatment of chorea associated with Huntington's disease and for tardive dyskinesia; received marketing approval for both indications in Brazil

Biosimilars
Truxima® reached 28% market share; 13 biosimilars in development: 7 in-house, 5 with Alvotech and 1 with BioEq

Risperidone LAI
Risperidone long-acting injectable for patients with schizophrenia was accepted for review by the FDA

Continuing to bring down our debt

Net Debt Development



Looking ahead to 2022

Our 2022 Guidance

Revenue

$15.6- $16.2 billion

EPS*

$2.40 - $2.60

*Non-GAAP EPS

Free Cash Flow

$1.9 - $2.2 billion

Successful Refinancing: $5B Sustainability-Linked Bond (SLB)

- Largest SLB of its kind
- First issued by a generic medicines company
- First in pharmaceutical industry to link both social and environmental targets
- Built on our strong ESG foundation and accelerates Teva's ESG journey

Spotlight on SLB Targets

Climate Change

Reduce absolute **Scope 1** and **2** GHG emissions by 25% by 2025

Access

- Increase the number of new **regulatory submissions by 150%** in low-to-middle-income countries across six key therapeutic areas by 2025
- Increase **access program product volume by 150%** in low-to-middle-income countries across six key therapeutic areas by 2025

2021 ESG Performance

	2021 Score	Previous Score	2021 Sector Ranking	Previous Sector Ranking
S&P Global	41 ▲	36	Top 17% ▲	Top 30%
SUSTAINALYTICS	31.1* ▲	33.3	Top 12%** ▼	Top 10%
MSCI	B (3.5 ▲	B (3.3)	Bottom 20% ▲	Bottom 22%
ISS ESG	C+ ▲	C	Top 10% ▲	Top 40%
FTSE4Good	3.6 ▲	3.4	Top 14% ▲	Top 29%
ecovadis	56 ▲	55	Top 23%	Top 24%
CDP CLIMATE	B ▼	A-	N/A	N/A
CDP WATER	B ▲	C	N/A	N/A
access to medicine FOUNDATION / antimicrobial resistance benchmark	60% ▼	63%	Bottom 35% ▼	Top 22%

* Sustainalytics scores are the risk rating scores
** Sustainalytics percentile score negatively impacted due to expanded scope of companies included in 2021

Cautionary Note Regarding Forward-Looking Statements

This infographic contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO, AJOVY and COPAXONE; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic;
- the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; environmental risks; and the impact of ESG issues;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.